Viglacera Tien Son JSC (HNX:VIT)

CTI BioPharma Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2019
Revenue	2,181,832	2,143,145	1,998,228	2,001,302	1,256,802	1,473,354
Revenue Growth (YoY)	4.13%	7.25%	-0.15%	59.24%	-14.70%	18.35%
Cost of Revenue	1,951,769	1,943,253	1,826,211	1,807,735	1,118,642	1,290,561
Gross Profit	230,063	199,892	172,017	193,567	138,160	182,792
Selling, General & Admin	46,263	40,460	50,552	58,895	47,246	41,388
Operating Expenses	46,263	40,460	50,552	58,895	47,246	41,388
Operating Income	183,799	159,431	121,465	134,671	90,913	141,405
Interest Expense	-86,997	-92,932	-118,504	-73,463	-36,795	-53,476
Interest & Investment Income	47.71	43.42	4,824	849.78	3,815	1,168
Currency Exchange Gain (Loss)	-3,609	-3,182	-792.77	-	-	-
Other Non Operating Income (Expenses)	1,907	993.58	-715.22	-1,795	-1,399	-670.67
EBT Excluding Unusual Items	95,147	64,354	6,276	60,263	56,535	88,426
Gain (Loss) on Sale of Investments	-	-239.78	4.72	-	-	-
Pretax Income	95,147	64,114	6,281	60,263	56,535	88,426
Income Tax Expense	15,504	11,679	6,195	9,365	10,368	16,245
Net Income	79,643	52,435	85.37	50,898	46,167	72,181
Net Income to Common	79,643	52,435	85.37	50,898	46,167	72,181
Net Income Growth	2168.86%	61323.79%	-99.83%	10.25%	-36.04%	80.58%
Shares Outstanding (Basic)	50	50	50	50	29	19
Shares Outstanding (Diluted)	50	50	50	50	29	19
Shares Change (YoY)	0.01%	-	0.00%	70.79%	50.14%	-
EPS (Basic)	1592.87	1048.71	1.71	1018.00	1577.00	3702.00
EPS (Diluted)	1592.87	1048.71	1.71	1018.00	1577.00	3702.00
EPS Growth	2168.73%	61323.81%	-99.83%	-35.45%	-57.40%	80.58%
Free Cash Flow	105,964	311,831	-254,967	-339,071	-629,921	161,377
Free Cash Flow Per Share	2119.29	6236.66	-5099.38	-6781.66	-21517.35	8276.67
Dividend Per Share	1000.000	1000.000	-	800.000	-	-
Gross Margin	10.54%	9.33%	8.61%	9.67%	10.99%	12.41%
Operating Margin	8.42%	7.44%	6.08%	6.73%	7.23%	9.60%
Profit Margin	3.65%	2.45%	0.00%	2.54%	3.67%	4.90%
Free Cash Flow Margin	4.86%	14.55%	-12.76%	-16.94%	-50.12%	10.95%
EBITDA	348,208	325,635	275,893	256,942	166,064	215,319
EBITDA Margin	15.96%	15.19%	13.81%	12.84%	13.21%	14.61%
D&A For EBITDA	164,408	166,204	154,428	122,271	75,151	73,914
EBIT	183,799	159,431	121,465	134,671	90,913	141,405
EBIT Margin	8.42%	7.44%	6.08%	6.73%	7.23%	9.60%
Effective Tax Rate	16.30%	18.22%	98.64%	15.54%	18.34%	18.37%
Revenue as Reported	2,181,832	2,143,145	1,998,228	2,001,302	1,256,802	1,473,354

Source: S&P Global Market Intelligence. Standard template. Financial Sources.